Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Aardvark Therapeutics, Inc. Common Stock (AARD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AARD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
Analysis of Past Performance
Type Stock | Historic Profit 8.11% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 284.41M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 4.88 - 19.58 | Updated Date 05/31/2025 |
52 Weeks Range 4.88 - 19.58 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 202920214 | Price to Sales(TTM) - |
Enterprise Value 202920214 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21384400 | Shares Floating 18389495 |
Shares Outstanding 21384400 | Shares Floating 18389495 | ||
Percent Insiders 24.03 | Percent Institutions 24.9 |
Upturn AI SWOT
Aardvark Therapeutics, Inc. Common Stock
Company Overview
History and Background
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for metabolic diseases, including obesity, non-alcoholic steatohepatitis (NASH), and other related conditions. Founded to address unmet medical needs in these areas.
Core Business Areas
- Drug Development: Focuses on the development of small molecule therapeutics for metabolic diseases.
Leadership and Structure
Key leadership includes the CEO and other senior executives overseeing clinical development, regulatory affairs, and business operations. Aardvark operates with a typical structure for a biotech company, involving various functional departments necessary for research, development, and potential commercialization.
Top Products and Market Share
Key Offerings
- ARD-101: ARD-101, a first-in-class oral small molecule that potently and selectively activates the GLP-1 receptor pathway in the stomach. It is intended for the treatment of obesity and related metabolic diseases such as NASH. No market share data is available as it is still in clinical trials. Competitors in obesity and NASH treatment include Novo Nordisk (NVO), Eli Lilly (LLY), and Madrigal Pharmaceuticals (MDGL).
Market Dynamics
Industry Overview
The biopharmaceutical industry is currently experiencing rapid growth, driven by advancements in biotechnology and increased demand for novel therapies. The metabolic disease market, including obesity and NASH, is particularly large and underserved.
Positioning
Aardvark Therapeutics aims to be a leader in developing innovative therapies for metabolic diseases, specifically with its unique approach to GLP-1 receptor activation. They are positioned to differentiate themselves through oral delivery and targeted activation in the stomach.
Total Addressable Market (TAM)
The TAM for obesity and NASH treatments is estimated to be in the tens of billions of dollars annually. Aardvark is positioned to capture a portion of this market with successful development and commercialization of ARD-101.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (GLP-1 receptor activation in the stomach)
- Oral delivery for convenience
- Potential for improved efficacy and safety profile compared to existing treatments
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on a single lead compound (ARD-101)
Opportunities
- Large and growing market for obesity and NASH treatments
- Potential for partnerships with larger pharmaceutical companies
- Positive clinical trial results could lead to rapid value appreciation
- Expansion into other metabolic disease indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unexpected adverse events in clinical trials
- Failure to secure adequate funding
Competitors and Market Share
Key Competitors
- NVO
- LLY
- MDGL
Competitive Landscape
Aardvark competes with larger pharmaceutical companies that have established products and significant resources. Aardvark's advantage lies in its novel approach and potential for improved safety and efficacy. However, it faces challenges in securing funding and navigating the regulatory landscape.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of ARD-101 through clinical trials. Milestones include successful completion of Phase 1 and Phase 2 studies.
Future Projections: Future growth is contingent upon positive results from ongoing and planned clinical trials. Analyst estimates will be available as the company progresses through development.
Recent Initiatives: Recent initiatives include ongoing Phase 2 clinical trials for ARD-101 in obesity and NASH.
Summary
Aardvark Therapeutics is a clinical-stage biotech company with a novel approach to treating metabolic diseases. Its strength lies in its lead compound, ARD-101, and its potential to address a large and growing market. However, the company faces risks associated with clinical trial failures and competition from larger pharmaceutical companies. Success depends on positive clinical trial results and securing adequate funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- Analyst Reports (when available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data is based on available information and is subject to change. Market share and financial data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aardvark Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2025-02-13 | CEO, Secretary & Director Dr. Tien-Li Lee M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://aardvarktherapeutics.com |
Full time employees 26 | Website https://aardvarktherapeutics.com | ||
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.